Recruiting Clinical Trials

Displaying 221 - 230 of 242 result(s)
Study Title Condition Phase Location
A 28-week, Randomized, Double-blind, Active Controlled, Multicenter Study to Evaluate the Efficacy of Subcutaneously Administered Secukinumab Compared to Ustekinumab in Adult Patients With Psoriatic Arthritis and Failure of TNFα- Inhibitor Treatment ... Psoriatic Arthritis Phase 3
  • Country: 
    Germany
An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously Relapsing Multiple Sclerosis (RMS) Phase 4
  • Country: 
    United States
A First-in-human, Open-label, Single Ascending Dose Study to Assess Safety and Tolerability of Intravitreal MHU650 in Patients With Macular Edema Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion Phase 1
  • Country: 
    United States
  • Country: 
    Puerto Rico
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in P ... Giant Cell Arteritis (GCA) Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: 
    More locations
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment Autoimmunity, Inflammation Phase 4
  • Country: 
    United States
  • Country: 
    Brazil
  • Country: 
    Bulgaria
  • Country: 
    More locations
An Open-label, Single-arm, Active-treatment Study to Evaluate Efficacy and Safety of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Adult Onset Still's Disease (AOSD) Adult Onset Still's Disease Phase 3
  • Country: 
    Japan
An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) Sjögren Syndrome Phase 2
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
    Denmark
  • Country: 
    More locations
A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer. Non Small Cell Lung Cancer Phase 1, Phase 2
  • Country: 
    United States
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants Hepatic Impairment Phase 1
  • Country: 
    United States
FocuS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases, Retinal Degeneration, Geographic Atrophy, Macular Atrophy Phase 1, Phase 2
  • Country: 
    United States